NOV Inc. (NOV) reported first-quarter 2025 adjusted earnings of 19 cents per share, which missed the Zacks Consensus Estimate of 25 cents. The bottom line decreased from the year-ago quarter’s 30 cents. This underperformance can be attributed to margin pressures on projects within its Energy Equipment segment. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) The oil and gas equipment and services company’s total revenues of $2.1 billion marginally beat the Zacks Consensus Estimate b ...

Core Insights - Zymeworks Inc. has received FDA approval for Ziihera (zanidatamab-hrii) targeting HER2-positive biliary tract cancer, marking a significant milestone in its biotechnology journey [1] Company Overview - Zymeworks Inc. has been active in the biotechnology sector for over a decade, facing both successes and challenges in drug development [1] - The company focuses on high-growth opportunities within sectors that are expected to experience exponential expansion [1] Investment Perspective - The analysis emphasizes the importance of innovation and disruptive technologies in generating substantial returns, aligning with the company's strategic direction [1]

MUMBAI, India and EDISON, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Trigyn Technologies Ltd. (BSE: 517562, NSE: TRIGYN), Trigyn Technologies, Inc., and its subsidiaries and affiliates are pleased to announce the appointment of Vikram Chandna as its Chief Executive Officer effective immediately. Vikram will be based in the USA. In his role as CEO, Vikram will provide strategic leadership to Trigyn Technologies. He will drive the strategic growth and transformation initiatives, focusing on achieving scalable p ...

Core Insights - Oramed Pharmaceuticals has made a strategic investment in Alpha Tau Medical, acquiring approximately 14.1 million shares at a price of $2.612 per share, aimed at supporting Alpha Tau's innovative cancer therapy technology [1][2] - The partnership combines Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology, enhancing both companies' capabilities in therapeutic delivery [1][3] - Oramed will provide strategic guidance and capital markets expertise to Alpha Tau through a three-year service agreement, which includes appointing two directors to Alpha Tau's Board [2][3] Company Overview - Oramed Pharmaceuticals specializes in oral delivery solutions for drugs typically administered via injection, utilizing its proprietary Protein Oral Delivery (POD™) technology to enhance drug integrity and absorption [4] - Alpha Tau Medical, founded in 2016, focuses on the research and development of the Alpha DaRT® technology for treating solid tumors, initially developed by professors from Tel Aviv University [5] Strategic Goals - The collaboration is expected to accelerate Alpha Tau's clinical trials across four indications in the U.S., expand manufacturing capacity, and enhance commercialization efforts [1][2] - Both companies share a vision of transforming therapeutic delivery methods, with Oramed focusing on oral administration and Alpha Tau on targeted radiation therapy [3]

G-III Apparel Group, Ltd. (GIII) is successfully transforming its business by prioritizing owned brands, boosting profitability and brand control while reducing dependence on licensed labels. Strong growth from key brands like DKNY and Karl Lagerfeld, strategic digital investments and aggressive international expansion are positioning the company for sustainable, long-term success. Moreover, its focus on innovation, global reach and operational efficiency continues to drive strong momentum into fiscal 2026 ...

PPL Corporation (PPL) is expected to report an improvement in its top line and a decline in its bottom line when it reports first-quarter 2025 results on April 30, before market open. (See the Zacks Earnings Calendar to stay ahead of market-making news)The Zacks Consensus Estimate for PPL’s first-quarter revenues is pegged at $2.38 billion, indicating growth of 3.4% from the year-ago reported figure.The Zacks Consensus Estimate for earnings is pegged at 55 cents per share. The Zacks Consensus Estimate for P ...

Group 1 - The analyst has 5 years of experience managing a technology fund and is licensed by the Brazilian Securities Commission as a portfolio manager and investment consultant [1] - The analyst's educational background includes degrees in Mechanical Engineering from the Federal University of Rio de Janeiro and École Centrale de Lyon [1] - The analyst has a strong focus on the semiconductor sector, having studied global equities since 2017, particularly NVIDIA [1] Group 2 - The investment strategy emphasizes investing in companies within oligopolistic sectors that have high barriers to entry, while avoiding smaller companies due to underestimated risks [1] - The analyst is particularly interested in disruptive technologies in hardware-related fields, including semiconductors, robotics, and energy [1] - The investment approach prioritizes growth at a reasonable price with a mid- to long-term investment horizon [1]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - After seven quarters of decline, analog demand is showing signs of recovery, with Texas Instruments Incorporated (NASDAQ: TXN) indicating a genuine turnaround in the market [1]. Company Summary - Texas Instruments has experienced a significant shift in analog demand, marking the end of a prolonged downturn [1]. - The company is optimistic about the recovery, suggesting that the market conditions are improving for analog products [1]. Industry Summary - The semiconductor industry, particularly the analog segment, is witnessing a revival after a challenging period, which could signal broader positive trends within the sector [1]. - The recovery in analog demand may lead to increased investment opportunities and growth prospects for companies operating in this space [1].

EATONTOWN, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Climb Global Solutions, Inc. (NASDAQ:CLMB) ("Climb" or the "Company"), a value-added global IT channel company providing unique sales and distribution solutions for innovative technology vendors, will host a conference call on Thursday, May 1, 2025 at 8:30 a.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2025. The Company's results will be reported in a press release prior to the call. Climb's management will host th ...